Peregrine Pharmaceuticals may have topped Wall Street’s expectations in Q4, but we have to dig beneath the headline figures to find the truly important takeaways.
Peregrine Pharmaceuticals may have topped Wall Street’s expectations in Q4, but we have to dig beneath the headline figures to find the truly important takeaways.